{
    "@context": {
        "ct": "https://clinicaltrials.gov/",
        "drug": "https://drugcentral.org/drugcard/",
        "file": "https://clinicaltrials.gov/ct2/show/",
        "mesh": "https://www.ncbi.nlm.nih.gov/mesh/?term=",
        "schema": "https://schema.org/"
    },
    "@graph": [
        {
            "@id": "file:NCT00010010",
            "@type": "schema:MedicalStudy",
            "schema:MedicalCondition": "breast cancer",
            "schema:about": [
                {
                    "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=breast%20neoplasms%5BMeSH%20Terms%5D"
                },
                {
                    "@id": "drug:1122"
                }
            ],
            "schema:alternateName": "a phase ii study of the combination of exemestane and goserelin in premenopausal women with metastatic hormone receptor positive breast cancer",
            "schema:phase": "phase 2",
            "schema:title": "exemestane plus goserelin in treating premenopausal women with metastatic breast cancer"
        },
        {
            "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=bile%20duct%20neoplasms%5BMeSH%20Terms%5D",
            "schema:citedby": {
                "@id": "file:NCT00010088"
            }
        },
        {
            "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=pancreatic%20neoplasms%5BMeSH%20Terms%5D",
            "schema:citedby": {
                "@id": "file:NCT00010088"
            }
        },
        {
            "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=breast%20neoplasms%5BMeSH%20Terms%5D",
            "schema:citedby": [
                {
                    "@id": "file:NCT00010075"
                },
                {
                    "@id": "file:NCT00010010"
                }
            ]
        },
        {
            "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=cholangiocarcinoma%5BMeSH%20Terms%5D",
            "schema:citedby": {
                "@id": "file:NCT00010088"
            }
        },
        {
            "@id": "drug:1122",
            "@type": "schema:Drug",
            "schema:name": "exemestane",
            "schema:study": {
                "@id": "file:NCT00010010"
            },
            "schema:url": "https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1200374"
        },
        {
            "@id": "drug:480",
            "@type": "schema:Drug",
            "schema:name": "capecitabine",
            "schema:study": {
                "@id": "file:NCT00010023"
            },
            "schema:url": [
                "https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1773",
                {
                    "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=d000069287"
                }
            ]
        },
        {
            "@id": "file:NCT00010075",
            "@type": "schema:MedicalStudy",
            "schema:MedicalCondition": "breast cancer",
            "schema:about": [
                {
                    "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=breast%20neoplasms%5BMeSH%20Terms%5D"
                },
                {
                    "@id": "drug:26"
                }
            ],
            "schema:alternateName": "study of the survival without degradation to the quality of life during chemotherapy for metastatic breast cancer in women",
            "schema:phase": "phase 2",
            "schema:title": "combination chemotherapy in treating older women with metastatic breast cancer"
        },
        {
            "@id": "file:NCT00010023",
            "@type": "schema:MedicalStudy",
            "schema:MedicalCondition": "cancer",
            "schema:alternateName": "a phase i study of oral fluoropyrimidine capecitabine (xeloda roche) combined with intravenous cisplatin in patients with advanced cancer of the digestive system",
            "schema:phase": "phase 1",
            "schema:title": "capecitabine combined with cisplatin in treating patients with locally advanced or metastatic solid tumors"
        },
        {
            "@id": "drug:26",
            "@type": "schema:Drug",
            "schema:name": "fluorouracil",
            "schema:study": [
                {
                    "@id": "file:NCT00010088"
                },
                {
                    "@id": "file:NCT00010075"
                }
            ],
            "schema:url": [
                "https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL185",
                {
                    "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=d005472"
                }
            ]
        },
        {
            "@id": "drug:4392",
            "@type": "schema:Drug",
            "schema:name": "cisplatin",
            "schema:study": {
                "@id": "file:NCT00010023"
            },
            "schema:url": {
                "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=d002945"
            }
        },
        {
            "@id": "file:NCT00010088",
            "@type": "schema:MedicalStudy",
            "schema:MedicalCondition": "extrahepatic bile duct cancer",
            "schema:about": [
                {
                    "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=pancreatic%20neoplasms%5BMeSH%20Terms%5D"
                },
                {
                    "@id": "drug:26"
                },
                {
                    "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=bile%20duct%20neoplasms%5BMeSH%20Terms%5D"
                },
                {
                    "@id": "https://www.ncbi.nlm.nih.gov/mesh/?term=cholangiocarcinoma%5BMeSH%20Terms%5D"
                }
            ],
            "schema:alternateName": "study of gemcitabine, leukovorin, and fluorouracil used to treat locally advanced and metastatic pancreatic and biliary adenocarcinomas",
            "schema:phase": "phase 2",
            "schema:title": "chemotherapy in treating patients with locally advanced or metastatic cancer of the pancreas or bile duct"
        }
    ]
}